Work

#145 - Survival and Treatment Response to Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma: a Real-world Analysis From Referral Oncology Centers in Colombia

Year: 2026

Type: article

Abstract: Introduction and Objectives Atezolizumab plus bevacizumab remains a standard first-line systemic treatment option for advanced hepatocellular carcinoma (HCC). However, real-world data from Latin America remains limited. To evaluate survival outcomes, treatment response, and safety of atezolizumab plus bevacizumab in patients with advanced HCC treated in routine clinical practice in Colombia. Materials and Methods Retrospective cohort study including adults with advanced HCC treated with atezolizumab plus bevacizumab between 2021 and 2026 at referral oncology centers in Colombia. Demographic, clinical, laboratory, treatment, and outcome data were collected from medical records. Overall survival (OS), progression-free survival (PFS), time to progression (TTP), treatment response according to RECIST/mRECIST criteria, and adverse events were evaluated with Kaplan-Meier survival analysis. Results Fifty-six patients were included (mean age 70.3 years and 66% were male). Cirrhosis was present in 66% of patients, and 81% were classified as Child-Pugh A. Metastases and portal vein thrombosis were identified in 28.6% and 26.8% of patients, respectively. With 66% mortality rate, median OS time was 17 months (Figure), while mean PFS and TTP were 10.3 and 9.9 months, respectively. Partial radiological response was observed in 8.9% of patients, whereas radiological progression was the most frequent outcome, occurring in 61.5% of cases. Adverse events occurred in 64.2% of patients, most commonly aminotransferase elevation and gastrointestinal bleeding. Conclusions In this cohort of Colombian patients with advanced HCC, atezolizumab plus bevacizumab demonstrated effectiveness and safety outcomes comparable to those observed in international real-world studies, supporting the reproducibility of these findings in Latin American clinical practice.

Source: Annals of Hepatology

DOI: 10.1016/j.aohep.2026.102391